Company press releases
| Released | Company | Title | Industry | Topic |
|---|---|---|---|---|
| 25 Apr 2024 13:46 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma annonserer godkjennelse av fase II-studie i pasienter med tidligfase føflekkreft (melanom) - en betydelig kommersiell mulighet | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 25 Apr 2024 13:46 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity. | 20103010 Biotechnology | Non-regulatory press releases |
| 24 Apr 2024 21:54 CEST |
LYTIX BIOPHARMA AS | LYTIX BIOPHARMA AS – PRELIMINARY RESULTS IN THE SHARE OFFERING | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 24 Apr 2024 07:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS - Last day of the Application Period | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 12 Apr 2024 07:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS – Ex Date | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 10 Apr 2024 23:48 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS: Tilbud om tegning av aksjer, publisering av prospekt og innkalling til ekstraordinær generalforsamling | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 10 Apr 2024 14:20 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS – Notice of extraordinary general meeting 25 April 2024 | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 10 Apr 2024 12:47 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS – Publication of Prospectus and commencement of Application Period | 20103010 Biotechnology | Prospekt / opptaksdokument |
| 09 Apr 2024 18:12 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma AS - Key information relating to the share offer | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 09 Apr 2024 17:45 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma raising up to NOK 55 million with strong support from existing shareholders – several key milestones coming up with large commercial potential | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 09 Apr 2024 17:10 CEST |
LYTIX BIOPHARMA AS | LYTIX BIOPHARMA AS: Contemplated Offering | 20103010 Biotechnology | Innsideinformasjon |
| 02 Apr 2024 12:54 CEST |
LYTIX BIOPHARMA AS | Lytix`s approach to raise response rates to immunotherapy highlighted in the international publication MedNous | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 21 Mar 2024 12:43 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma announces the publication of a paper describing how LTX-315 mediates antitumor activity through multiple pathways | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 20 Mar 2024 14:54 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 29 Feb 2024 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma Q4 and H2 2023 results: Promising interim results from multiple phase II studies, expanding clinical roadmap to early-stage cancer patients | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 22 Feb 2024 10:36 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2023 results, Thursday 29 February 2024 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 26 Jan 2024 12:42 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Jan 2024 10:39 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presenting at Redeye Fight Cancer Event 2024 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 05 Jan 2024 15:18 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 29 Dec 2023 17:58 CET |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 Dec 2023 13:14 CET |
LYTIX BIOPHARMA | Encouraging results from ATLAS-IT-04 study published in OncoImmunology | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 09 Nov 2023 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presents third quarter 2023 results | 20103010 Biotechnology | Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll |
| 08 Nov 2023 12:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma presenting at major investor conferences in London and Stockholm in November | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 02 Nov 2023 08:00 CET |
LYTIX BIOPHARMA AS | Lytix Biopharma: Presentation of third quarter 2023 results, November 9 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 25 Oct 2023 13:23 CEST |
LYTIX BIOPHARMA AS | Financial calendar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 23 Oct 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023 | 20103010 Biotechnology | Innsideinformasjon |
| 20 Oct 2023 09:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma to host webcast after release of preliminary data from ATLAS-IT-05 | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 17 Oct 2023 08:00 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’ | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 16 Oct 2023 08:51 CEST |
LYTIX BIOPHARMA AS | Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |
| 09 Oct 2023 15:00 CEST |
LYTIX BIOPHARMA AS | Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting | 20103010 Biotechnology | Ikke-informasjonspliktige pressemeldinger |